Imaging and Management of Pancreatic Cancer

This article will provide a broad overview of the imaging and management of pancreatic cancer with a focus on diagnosis and staging, operative and non-operative treatments, and post-therapeutic appearances after surgery and chemo-radiation therapy.
Source: Seminars in Ultrasound, CT and MRI - Category: Radiology Source Type: research

Related Links:

Authors: Suleiman S, Suleiman S, Schembri Wismayer P, Calleja Agius J Abstract Gastric cancer is the sixth most common cancer worldwide with increased associated morbidity and mortality. Although a multimodality treatment approach is necessary, surgery is still considered as the standard of care. There is a longstanding intercontinental debate between Eastern and Western upper GI surgeons in regards to the proper type of lymphadenectomy that should accompany the resection of the primary tumor. While D2 gastrectomy was performed as the standard procedure in eastern countries, the increased morbidity and mortality at...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
ConclusionWhile a timely work-up of advanced PC patients remains important, delays in treatment initiation due to repeated biopsies, inclusion in a clinical study or transfer to a specialized cancer center appear to be justified in light of the absence of a strong adverse effect of prolonged TTI on prognosis in advanced PC patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to evaluate the clinical outcomes, toxicity, and prognostic factors of SBRT combined with gemcitabine plus capecitabine (GEM-CAP) in treating locally advanced pancreatic cancer (LAPC).MethodsA total of 56 patients with LAPC treated with SBRT combined with GEM-CAP were reviewed from October 2010 to October 2016. The median total prescription dose at five fractions was 40  Gy (30–50 Gy). The patients were subjected to two cycles of GEM-CAP before SBRT. GEM-CAP chemotherapy was then offered for four cycles or until disease tolerance or progression. The primary endpoints included overall surviv...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, DNAM-1 or NKG2D over-expression elicited a dynamic increase in NK cell degranulation against all sarcoma explants and cancer cell lines tested, including those that failed to induce a notable response in WT NK-92 cells. These results support the broad therapeutic potential of DNAM-1+ or NKG2D+ GM NK-92 cells and GM human NK cells for the treatment of sarcomas and other malignancies.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Condition:   Pancreas Adenocarcinoma Intervention:   Sponsor:   National Cancer Center, Korea Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pancreatic Cancer Interventions:   Drug: ATRA;   Drug: Gemcitabine;   Drug: nab-paclitaxel Sponsors:   Queen Mary University of London;   Medical Research Council;   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The medical oncologist from Memorial Sloan Kettering Cancer Center discussed challenges in treating patients with pancreatic center, and also the challenge of obtaining effective drugs in the clinical setting.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Contributors : Daniel Baumann ; Rienk OffringaSeries Type : Expression profiling by arrayOrganism : Mus musculusCancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression of immune cell function by cytostatic drugs may limit therapeutic efficacy. Here we show that targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) does not impair dendritic cell-mediated T-cell p...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
AbstractPurposePancreatic tumors are rare in children and limited data are available regarding incidence, treatment, and outcomes. We aim to describe patient and tumor characteristics and to report on survival of these diseases.MethodsChildren with pancreatic tumors were queried from the National Cancer Database (2004 –2014). The association between treatment and hazard of death was assessed using Kaplan–Meier method and Cox regression model.ResultsWe identified 109 children with pancreatic tumors; 52% were male and median age at diagnosis was 14  years. Tumors were distributed as follows: pseudopapillary ...
Source: Pediatric Surgery International - Category: Surgery Source Type: research
Conclusion: It may be employed either alone or in combination with cryotherapy, existing chemotherapy, bypass surgery or radiations to achieve the optimal results in these patients. Nevertheless, there is a need to formulate a uniform dose and procedure to achieve homogeneity and develop references for clinical practices. PMID: 31977258 [PubMed - as supplied by publisher]
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
More News: Cancer | Cancer & Oncology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Radiation Therapy | Radiology | Ultrasound